$PSNL News

Personalis, Inc. (PSNL) M&A Call Transcript

Personalis, Inc. (PSNL) Tempus AI, Inc. - M&A Call - Slideshow

Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal

TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers

Tempus AI Bets on MRD Testing Growth With Personalis Acquisition

Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B

TEM’s Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity – Retail Awaits To See Execution

Lake Street Downgrades Personalis to Hold, Announces $16.25 Price Target

BTIG Maintains Buy on Personalis, Raises Price Target to $16.25

Tempus AI to Acquire Personalis in $1.5 Billion Deal

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Needham Downgrades Personalis to Hold

Needham Maintains Buy on Personalis, Raises Price Target to $17

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test

Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $13

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Wins EU Compliance Mark for Cancer Testing Blood Kits, Blood Collection Kits Receive European Diagnostic Mark